New Zealand markets closed
  • NZX 50

    -51.35 (-0.46%)

    +0.0037 (+0.60%)

    -123.30 (-1.66%)
  • OIL

    -0.66 (-0.60%)
  • GOLD

    -4.20 (-0.23%)

Global Pulmonary Drug Delivery Systems Market Report 2022, Featuring Philips Respironics, GlaxoSmithKline, Boehringer Ingelheim, 3M Healthcare and PARI GmbH

·4-min read

Dublin, Jan. 17, 2022 (GLOBE NEWSWIRE) -- The "Pulmonary Drug Delivery Systems Market Forecasts to 2026" report has been added to's offering.

The pulmonary drug delivery systems market is projected to grow at a CAGR of 4.83% to reach US$56.942 billion by 2026, from US$40.929 billion in 2019.

The increasing prevalence of the chronic respiratory disease worldwide will drive the market growth of the pulmonary drug delivery systems market during the forecast period. According to the World Health Organization, more than 1 billion people suffer from either acute or chronic respiratory conditions. Around 4 million people die prematurely from chronic respiratory diseases. In addition, nearly 235 million people suffer from asthma in the world and over 80% of the deaths due to Asthma occur in low and middle-income countries. The increasing incidence of such diseases will support the market growth as more patients will require the pulmonary drug delivery system for their treatment.

Increasing geriatric population
Moreover, the rapidly growing geriatric population worldwide will contribute to the market growth as they are more prone to chronic respiratory diseases such as bronchitis, tuberculosis, and chronic obstructive pulmonary disease, etc. which will surge the demand for pulmonary drug delivery systems in the market. According to the United Nations, in 2019, the geriatric population was 703 million persons, nationwide. The number of older persons is projected to double to 1.5 billion in 2050.

Health awareness
Furthermore, the growing health awareness and increasing investment in the healthcare and drug delivery industry by both public and private players are also expected to further fuel up the growth of the market. Also, the initiative taken by the governing bodies of various countries is increasing health awareness among the people. For instance, the National Asthma Control Program (NACP) by CDS, provides funds for educating asthma-affected patients. Such initiatives will encourage more patients to adopt pulmonary drug delivery systems for their treatment which will further strengthen the market growth during the forecast period.

Market Segmentation
By product, the dry powder inhalers (DPIs) segment is projected to hold a significant market share owing to the advantages such as short administration & preparation time, ease of use, and fewer irritant effects associated with the use of these inhalers. Geographically, North America holds a significant market share due to the increasing prevalence of chronic respiratory diseases, early adoption of the pulmonary drug delivery systems, and the surge in healthcare spending in the region. Asia Pacific will be the fastest-growing market region owing to the rapidly growing geriatric population, increasing adoption of an unhealthy lifestyle, and rising urbanization in the region.

Growth Factors

Increase in the geriatric population
The increase in the geriatric population across the globe is expected to drive the market growth of pulmonary drug delivery systems. According to COPD, about 1 in 7 older adults suffers from some of the other forms of lung disease. The geriatric population is more prone to chronic respiratory diseases as compared to the younger population which will increase the demand for pulmonary drug delivery systems in the market during the forecast period.


Lack of awareness
The pulmonary drug delivery system is a relatively new system due to which not many patients are aware of the advantages of using this system which may restrain the market growth during the forecast period. The patients, especially in the developing countries are unaware of the existence of this system due to which the demand for it is low in these countries. However, with the increasing awareness by both the public and private players the patients are expected to become aware and adopt these systems.


By Product

  • Metered-dose inhalers (MDIs)

  • Dry Powder Inhalers (DPIs)

  • Soft mist inhaler (SMI)

  • Nebulizers

By Distribution Channel

  • Offline

  • Online

By Geography

  • North America

  • USA

  • Canada

  • Mexico

  • South America

  • Brazil

  • Argentina

  • Others

  • Europe

  • UK

  • Germany

  • France

  • Spain

  • Others

  • Middle East and Africa

  • Saudi Arabia

  • Israel

  • Others

  • Asia Pacific

  • Japan

  • China

  • India

  • Indonesia

  • Taiwan

  • Thailand

Companies Mentioned

  • Philips Respironics

  • GlaxoSmithKline PLC

  • Boehringer Ingelheim GmbH

  • Teva Pharmaceutical Industries Ltd.

  • 3M Healthcare

  • PARI GmbH

  • F. Hoffmann-La Roche AG

  • Gilbert Technologies

  • AstraZeneca PLC

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting